AbbVie Announces Investment In New Manufacturing Campus In North Carolina

Published: 2026-04-22 13:35:42 ET ABBV

Published on 04/22/2026 at 01:35 pm EDT

AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie's immunology, neuroscience and oncology medicines. This is AbbVie's first major investment in North Carolina.

The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region's local workforce and its ability to support future expansion. Construction will begin this year, with completion expected by the end of 2028. Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians.

The project will also support the local economy by generating more than 2,000 construction jobs during campus development. This project is part of the Company's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities with room to support AbbVie's growing pipeline.

When completed, this campus will serve as AbbVie's U.S. center of excellence for SVP manufacturing and deliver next-generation medicines to patients in the U.S. and worldwide. With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its U.S. manufacturing campuses. With this announcement, AbbVie has committed to investing more than $2.2 billion in U.S. manufacturing over the past 12 months and creating more than 1,300 jobs in North Carolina, Illinois, Arizona and Massachusetts.